LogicBio Therapeutics (NASDAQ:LOGC) Trading 9.5% Higher

LogicBio Therapeutics, Inc. (NASDAQ:LOGCGet Rating)’s stock price traded up 9.5% during trading on Thursday . The stock traded as high as $0.46 and last traded at $0.46. 168,394 shares were traded during mid-day trading, a decline of 77% from the average session volume of 723,332 shares. The stock had previously closed at $0.42.

Analyst Ratings Changes

Separately, William Blair raised shares of LogicBio Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday, May 9th.

LogicBio Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.74 and a current ratio of 2.74. The firm’s 50-day moving average is $0.42 and its two-hundred day moving average is $0.62.

LogicBio Therapeutics (NASDAQ:LOGCGet Rating) last released its quarterly earnings data on Monday, May 16th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. The company had revenue of $2.82 million during the quarter. LogicBio Therapeutics had a negative net margin of 468.89% and a negative return on equity of 104.61%. On average, sell-side analysts expect that LogicBio Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of LogicBio Therapeutics

Several hedge funds have recently made changes to their positions in the company. Blair William & Co. IL purchased a new position in shares of LogicBio Therapeutics during the 4th quarter worth approximately $51,000. Acadian Asset Management LLC purchased a new position in LogicBio Therapeutics in the 1st quarter valued at approximately $32,000. Virtu Financial LLC boosted its position in LogicBio Therapeutics by 312.4% in the 1st quarter. Virtu Financial LLC now owns 71,475 shares of the company’s stock valued at $49,000 after buying an additional 54,145 shares during the period. Harbor Capital Advisors Inc. purchased a new position in LogicBio Therapeutics in the 4th quarter valued at approximately $653,000. Finally, Renaissance Technologies LLC purchased a new position in LogicBio Therapeutics in the 1st quarter valued at approximately $312,000. Hedge funds and other institutional investors own 55.20% of the company’s stock.

LogicBio Therapeutics Company Profile

(Get Rating)

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues.

Read More

Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.